Æterna Zentaris: Publication in the Journal of the National Cancer Institute Demonstrates Perifosine Single Agent Potential in Neuroblastoma Tumors
Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency
It is incredulous that AEZS remains at a $125M market cap.
With so many late stage products in development and so much in the pipeline, this looks to me as 5X to 10X bagger laying in wait.
A
4 comments:
Curious. starting to look at it. first question,if you know,
What happened to this stock on august 17 ,2009
when it crashed from 3.00 to .88 ??
What happened back in 2000 for 2 years when it dropped from 11 dollars down to the bottom??
I'm interested but these are my first questions I guess...
This isn't Allan's job to do our homework or due dilligence for us. That information you seek is available to anyone who wants to take the time to find that out. Allan made us aware of an opportunity. Learn more about that opportunity if it interests you, and report back the results of your inquiries like some of us try and do here.
Ditto above re 'it's not Allan's job...' Even if I was not a subscriber, I think many of the things people say to him and ask of him are simply inappropriate.
Personally I'd wish you charged at least some fee for the blog Allan. I don't imagine you need the nominal income, but just so it would weed out many of the 'something-for-nothing' crowd. I'd certainly pay even if it was an extra beyond the monthly subscription. Value for value, that's all.
2 jack asses blowing hot air.
the question seems reasonable to me.
I'm an expert on some stocks and not others.
If someone posted a question ,and I knew the answer,its not gonna kill me to help out.
Sometimes I help Allan,and he helps me.
you guys just sound like 2 jack asses with nothing to offer but hot air.
Post a Comment